Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study by Hellmann, Matthew D, Dr, Rizvi, Naiyer A, Prof, Goldman, Jonathan W, MD, Gettinger, Scott N, MD, Borghaei, Hossein, DO, Brahmer, Julie R, MD, Ready, Neal E, Prof, Gerber, David E, MD, Chow, Laura Q, MD, Juergens, Rosalyn A, MD, Shepherd, Frances A, Prof, Laurie, Scott A, MD, Geese, William J, PhD, Agrawal, Shruti, PhD, Young, Tina C, MS, Li, Xuemei, MD, Antonia, Scott J, Prof

Get full text

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, Dr, Gettinger, Scott N, MD, Mahajan, Amit, MD, Chiang, Anne C, MD, Herbst, Roy S, Prof, Sznol, Mario, Prof, Tsiouris, Apostolos John, MD, Cohen, Justine, DO, Vortmeyer, Alexander, MD, Jilaveanu, Lucia, MD, Yu, James, MD, Hegde, Upendra, MD, Speaker, Stephanie, BA, Madura, Matthew, BS, Ralabate, Amanda, BSN, Rivera, Angel, MS, Rowen, Elin, MSN, Gerrish, Heather, BSN, Yao, Xiaopan, PhD, Chiang, Veronica, MD, Kluger, Harriet M, Prof

Get full text

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC by Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius

Get full text

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials by Gettinger, Scott N., Huber, Rudolf M., Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J., Paz-Ares Rodríguez, Luis G., West, Howard L., Reckamp, Karen L., Weiss, Glen J., Smit, Egbert F., Hochmair, Maximilian J., Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S., Groen, Harry J.M., Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, Camidge, D. Ross

Get full text

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial by Gettinger, Scott N, Dr, Bazhenova, Lyudmila A, Prof, Langer, Corey J, Prof, Salgia, Ravi, Prof, Gold, Kathryn A, MD, Rosell, Rafael, Prof, Shaw, Alice T, MD, Weiss, Glen J, MD, Tugnait, Meera, PhD, Narasimhan, Narayana I, PhD, Dorer, David J, PhD, Kerstein, David, MD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Camidge, David Ross, Prof

Get full text